Solvay shareholders approve capital increase plan to buy Cytec

Brussels, November 17, 2015 --- Solvay today held its Extraordinary Shareholders Meeting with the purpose of obtaining shareholder authorisation for the Board of Directors to proceed with a rights issue of 1.5 billion euros maximum to finance the acquisition of Cytec Industries Inc. in the United States.

Shareholders present at the EGM represented 59.90% of Solvay's share capital and 99.13% voted in favor of such authorisation.
The Board of Directors will decide in due time on the terms and appropriate timing of the intended rights issue.

Details of the voting results as well as a replay of the Shareholders Meeting will be available shortly on Solvay's website, Investors section.  

DISCLAIMER

These written materials do not constitute an offer to sell, or a solicitation of offers to purchase or subscribe for, securities in the United States or any other jurisdiction. The securities referred to herein have not been, and will not be, registered under the Securities Act of 1933, as amended, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements. There is no intention to register any offering in the United States or to conduct a public offering of securities in the United States.

The issue, exercise or sale of securities are subject to specific legal or regulatory restrictions in certain jurisdictions. Solvay assumes no responsibility in the event there is a violation by any person of such restrictions.

For further information, please visit this section. 

       Follow us on twitter @SolvayGroup